MINDY1

Summary

MINDY1 (MINDY lysine 48 deubiquitinase 1, HGNC:25648) is a protein-coding gene on chromosome 1q21.3, encoding Ubiquitin carboxyl-terminal hydrolase MINDY-1 (Q8N5J2). Hydrolase that can specifically remove ‘Lys-48’-linked conjugated ubiquitin from proteins.

Enables K48-linked deubiquitinase activity; K48-linked polyubiquitin modification-dependent protein binding activity; and cysteine-type carboxypeptidase activity. Predicted to be involved in proteolysis. Located in nuclear body.

Source: NCBI Gene 55793 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 99 total
• MANE Select transcript: NM_001376665

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25648
Approved symbol	MINDY1
Name	MINDY lysine 48 deubiquitinase 1
Location	1q21.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ11280, MINDY-1
Ensembl gene	ENSG00000143409
Ensembl biotype	protein_coding
OMIM	618407
Entrez	55793

Gene structure

Transcript identifiers

Ensembl transcripts: 34 — 34 protein_coding

ENST00000312210, ENST00000361738, ENST00000361936, ENST00000493834, ENST00000497067, ENST00000683666, ENST00000888222, ENST00000888223, ENST00000888224, ENST00000888225, ENST00000888226, ENST00000888227, ENST00000888228, ENST00000888229, ENST00000888230, ENST00000888231, ENST00000931104, ENST00000931105, ENST00000931106, ENST00000942999, ENST00000943000, ENST00000943001, ENST00000943002, ENST00000943003, ENST00000943004, ENST00000943005, ENST00000943006, ENST00000943007, ENST00000943008, ENST00000943009, ENST00000943010, ENST00000943011, ENST00000943012, ENST00000943013

RefSeq mRNA: 17 — MANE Select: NM_001376665 NM_001040217, NM_001163258, NM_001163259, NM_001163260, NM_001319998, NM_001376664, NM_001376665, NM_001376666, NM_001376667, NM_001376668, NM_001376669, NM_001376670, NM_001376671, NM_001376672, NM_001376673, NM_001376674, NM_018379

CCDS: CCDS30854, CCDS55635, CCDS976

Canonical transcript exons

ENST00000683666 — 10 exons

Exon	Start	End
ENSE00001072089	150998082	150998273
ENSE00001072091	150997624	150997779
ENSE00001072097	151000457	151000615
ENSE00001072101	150999369	150999511
ENSE00001185822	150996835	150997367
ENSE00001599206	151002165	151002706
ENSE00003462542	151001725	151001782
ENSE00003469852	151001250	151001314
ENSE00003536702	150999862	150999964
ENSE00003917352	151006312	151006902

Expression profiles

Bgee: expression breadth ubiquitous, 259 present calls, max score 94.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.0026 / max 284.2557, expressed in 1747 samples.

FANTOM5 promoters (16 alternative TSS)

Promoter ID	TPM avg	Samples expressed
14390	7.2524	1543
14391	5.2734	1576
14380	2.0927	808
14382	0.7256	279
14383	0.5903	235
14386	0.5038	176
14381	0.4377	251
14393	0.2487	89
14384	0.2386	102
14389	0.2126	78

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	94.99	gold quality
apex of heart	UBERON:0002098	93.93	gold quality
right lobe of thyroid gland	UBERON:0001119	93.86	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.75	gold quality
left lobe of thyroid gland	UBERON:0001120	93.18	gold quality
thyroid gland	UBERON:0002046	92.85	gold quality
lower esophagus mucosa	UBERON:0035834	92.83	gold quality
spinal cord	UBERON:0002240	92.79	gold quality
pancreas	UBERON:0001264	92.41	gold quality
metanephros cortex	UBERON:0010533	92.38	gold quality
esophagus mucosa	UBERON:0002469	91.49	gold quality
blood	UBERON:0000178	91.46	gold quality
right atrium auricular region	UBERON:0006631	91.28	gold quality
tibial nerve	UBERON:0001323	91.03	gold quality
cardiac atrium	UBERON:0002081	90.68	gold quality
heart left ventricle	UBERON:0002084	90.49	gold quality
monocyte	CL:0000576	90.45	gold quality
cervix squamous epithelium	UBERON:0006922	90.37	silver quality
mononuclear cell	CL:0000842	90.36	gold quality
ileal mucosa	UBERON:0000331	90.32	silver quality
body of stomach	UBERON:0001161	90.22	gold quality
cardiac ventricle	UBERON:0002082	90.22	gold quality
leukocyte	CL:0000738	90.20	gold quality
inferior vagus X ganglion	UBERON:0005363	90.07	gold quality
mucosa of transverse colon	UBERON:0004991	90.06	gold quality
islet of Langerhans	UBERON:0000006	89.77	gold quality
subthalamic nucleus	UBERON:0001906	89.63	gold quality
epithelium of esophagus	UBERON:0001976	89.49	gold quality
heart	UBERON:0000948	89.44	gold quality
stomach	UBERON:0000945	89.17	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

30 targeting MINDY1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-6799-5P	99.14	65.72	2093
HSA-MIR-6877-3P	98.98	65.83	560
HSA-MIR-6819-3P	98.95	65.57	572
HSA-MIR-455-3P	98.94	67.68	878
HSA-MIR-4763-5P	98.75	63.89	854
HSA-MIR-589-5P	98.72	66.96	927
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-6796-3P	98.68	65.49	689
HSA-MIR-4782-5P	98.35	69.33	1474
HSA-MIR-5706	98.35	69.33	1463
HSA-MIR-4518	98.12	66.82	1030
HSA-MIR-744-3P	97.99	67.76	637
HSA-MIR-4708-5P	97.77	67.82	831
HSA-MIR-1266-5P	97.71	66.92	1052
HSA-MIR-6793-3P	97.66	65.78	1084
HSA-MIR-6729-3P	96.91	66.79	703
HSA-MIR-212-5P	96.83	67.43	950
HSA-MIR-3135A	96.41	65.30	494
HSA-MIR-5586-5P	96.29	68.02	685
HSA-MIR-2114-3P	95.45	66.11	579
HSA-MIR-6823-3P	95.45	66.14	704
HSA-MIR-874-3P	95.02	65.66	806

Literature-anchored findings (GeneRIF, showing 3)

• MINDY-1 prefers cleaving long polyubiquitin chains and works by trimming chains from the distal end. (PMID:27292798)
• Mechanism of activation and regulation of deubiquitinase activity in MINDY1 and MINDY2. (PMID:34529927)
• MINDY1 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha. (PMID:34645792)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	mindy1	ENSDARG00000004866
mus_musculus	Mindy1	ENSMUSG00000038712
rattus_norvegicus	Mindy1	ENSRNOG00000021131
caenorhabditis_elegans		WBGENE00021926

Paralogs (1): MINDY2 (ENSG00000128923)

Protein

Protein identifiers

Ubiquitin carboxyl-terminal hydrolase MINDY-1 — Q8N5J2 (reviewed: Q8N5J2)

Alternative names: Deubiquitinating enzyme MINDY-1, Protein FAM63A

All UniProt accessions (2): Q8N5J2, H0YJH5

UniProt curated annotations — full annotation on UniProt →

Function. Hydrolase that can specifically remove ‘Lys-48’-linked conjugated ubiquitin from proteins. Has exodeubiquitinase activity and has a preference for long polyubiquitin chains. May play a regulatory role at the level of protein turnover.

Similarity. Belongs to the MINDY deubiquitinase family. FAM63 subfamily.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8N5J2-1	1	yes
Q8N5J2-2	2
Q8N5J2-3	3
Q8N5J2-4	4

RefSeq proteins (17): NP_001035307, NP_001156730, NP_001156731, NP_001156732, NP_001306927, NP_001363593, NP_001363594, NP_001363595, NP_001363596, NP_001363597, NP_001363598, NP_001363599, NP_001363600, NP_001363601, NP_001363602, NP_001363603, NP_060849 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007518	MINDY	Family
IPR033979	MINDY_domain	Domain

Pfam: PF04424

UniProt features (75 total): mutagenesis site 30, strand 12, helix 11, region of interest 3, site 3, splice variant 3, compositionally biased region 3, sequence conflict 3, modified residue 2, active site 2, chain 1, sequence variant 1, turn 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
5MN9	X-RAY DIFFRACTION	2.05
6TUV	X-RAY DIFFRACTION	2.16
6TXB	X-RAY DIFFRACTION	2.18
5JQS	X-RAY DIFFRACTION	2.65
5JKN	X-RAY DIFFRACTION	3
6YJG	X-RAY DIFFRACTION	3.28
6Y6R	X-RAY DIFFRACTION	3.32
6Z90	X-RAY DIFFRACTION	3.59

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N5J2-F1	73.65	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (5): 415–416 (ubiquitin-binding); 419 (ubiquitin-binding); 137 (nucleophile); 319 (proton acceptor); 412 (ubiquitin-binding)

Post-translational modifications (2): 103, 441

Mutagenesis-validated functional residues (30):

Position	Phenotype
131	abolishes ubiquitin hydrolase activity.
137	abolishes ubiquitin hydrolase activity.
209	abolishes ubiquitin hydrolase activity.
210	greatly impairs ubiquitin hydrolase activity.
240	abolishes ubiquitin hydrolase activity.
258	abolishes ubiquitin hydrolase activity.
263	greatly impairs ubiquitin hydrolase activity.
263	abolishes ubiquitin hydrolase activity.
315	abolishes ubiquitin hydrolase activity.
319	abolishes ubiquitin hydrolase activity.
396	no effect on binding to ’lys-48’ tetraubiquitin chains.
408	no effect on binding to ’lys-48’ tetraubiquitin chains.
411	no effect on binding to ’lys-48’ tetraubiquitin chains.
412	loss of binding to ’lys-48’ tetraubiquitin chains.
413	no effect on binding to ’lys-48’ tetraubiquitin chains.
414	no effect on binding to ’lys-48’ tetraubiquitin chains.
415–416	decreased association with ’lys-48’-linked conjugated ubiquitin.
415	loss of binding to ’lys-48’ tetraubiquitin chains.
416	loss of binding to ’lys-48’ tetraubiquitin chains.
416	no effect on binding to ’lys-48’ tetraubiquitin chains.
418	no effect on binding to ’lys-48’ tetraubiquitin chains.
419	loss of binding to ’lys-48’ tetraubiquitin chains.
420	loss of binding to ’lys-48’ tetraubiquitin chains.
421	no effect on binding to ’lys-48’ tetraubiquitin chains.
422	no effect on binding to ’lys-48’ tetraubiquitin chains.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 200 (showing top): CMYB_01, AP4_Q6, GGAMTNNNNNTCCY_UNKNOWN, CAGCTG_AP4_Q5, PATIL_LIVER_CANCER, TCF4_Q5, AML_Q6, GOMF_CYSTEINE_TYPE_PEPTIDASE_ACTIVITY, TGCTGAY_UNKNOWN, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, MYB_Q3, FOXO4_02, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, MYB_Q5_01, chr1q21

GO Biological Process (1): proteolysis (GO:0006508)

GO Molecular Function (8): cysteine-type deubiquitinase activity (GO:0004843), cysteine-type carboxypeptidase activity (GO:0016807), K48-linked polyubiquitin modification-dependent protein binding (GO:0036435), K48-linked deubiquitinase activity (GO:1990380), protein binding (GO:0005515), peptidase activity (GO:0008233), cysteine-type peptidase activity (GO:0008234), hydrolase activity (GO:0016787)

GO Cellular Component (3): nucleoplasm (GO:0005654), nuclear body (GO:0016604), cell periphery (GO:0071944)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
deubiquitinase activity	2
cellular anatomical structure	2
protein metabolic process	1
cysteine-type peptidase activity	1
carboxypeptidase activity	1
cysteine-type exopeptidase activity	1
polyubiquitin modification-dependent protein binding	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
nuclear lumen	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

718 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MINDY1	SLC13A5	Q86YT5	790
MINDY1	COPS5	Q92905	669
MINDY1	MINDY4	Q4G0A6	649
MINDY1	ZUP1	Q96AP4	615
MINDY1	JOSD1	Q15040	578
MINDY1	JOSD2	Q8TAC2	577
MINDY1	MINDY3	Q9H8M7	543
MINDY1	MPND	Q8N594	513
MINDY1	USP7	Q93009	509
MINDY1	USP14	P54578	471
MINDY1	USP22	Q9UPT9	462
MINDY1	USP13	Q92995	434
MINDY1	RCHY1	Q96PM5	432
MINDY1	OTUB1	Q96FW1	430
MINDY1	USP28	Q96RU2	426

IntAct

37 interactions, top by confidence:

A	B	Type	Score
MINDY1	FLJ13057	psi-mi:“MI:0915”(physical association)	0.560
MANSC1	KLRG2	psi-mi:“MI:0914”(association)	0.530
TMEM31	PSMD11	psi-mi:“MI:0914”(association)	0.530
KDELR1	TRAFD1	psi-mi:“MI:0914”(association)	0.530
KCNA10	GAPDHS	psi-mi:“MI:0914”(association)	0.530
CD1D	MINDY1	psi-mi:“MI:0915”(physical association)	0.400
ECE1	MINDY1	psi-mi:“MI:0915”(physical association)	0.370
OR6M1	RPSA2	psi-mi:“MI:0914”(association)	0.350
CTLA4	TMEM120B	psi-mi:“MI:0914”(association)	0.350
TMEM74	KLRG2	psi-mi:“MI:0914”(association)	0.350
OR5H1	RBFOX3	psi-mi:“MI:0914”(association)	0.350
NRSN1	FAM171A2	psi-mi:“MI:0914”(association)	0.350
TMEM63C	GPR89A	psi-mi:“MI:0914”(association)	0.350
PTCHD3	ABCD4	psi-mi:“MI:0914”(association)	0.350
RGS9BP	HGS	psi-mi:“MI:0914”(association)	0.350
CHRNB1	BET1	psi-mi:“MI:0914”(association)	0.350
OR10S1	ABCC4	psi-mi:“MI:0914”(association)	0.350
OR1A2	EMC8	psi-mi:“MI:0914”(association)	0.350
RNF126	GET3	psi-mi:“MI:0914”(association)	0.350
CNGA4	CCDC22	psi-mi:“MI:0914”(association)	0.350
TSPAN16	ENDOD1	psi-mi:“MI:0914”(association)	0.350
GRTP1	UBB	psi-mi:“MI:0914”(association)	0.350
OR2G6	UBB	psi-mi:“MI:0914”(association)	0.350
BTBD6	UBB	psi-mi:“MI:0914”(association)	0.350
SEL1L3	CANX	psi-mi:“MI:0914”(association)	0.350
CHIA	TPP2	psi-mi:“MI:0914”(association)	0.350
PIGH	PTGDS	psi-mi:“MI:0914”(association)	0.350
ZP3	SERPINB8	psi-mi:“MI:0914”(association)	0.350

BioGRID (62): GMCL1 (Two-hybrid), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Affinity Capture-MS), FAM63A (Reconstituted Complex), UBC (Reconstituted Complex), RPS27A (Co-crystal Structure)

ESM2 similar proteins: A3KMI0, A3KQS4, A5PF44, A6QP16, A8E7C5, B1H2Q2, F4HZF0, O15226, O96838, P34550, Q09874, Q29FC1, Q2KI23, Q2KJ22, Q3SWY8, Q3T9Z9, Q3V0G7, Q4R4A2, Q5BJQ2, Q5R7G8, Q5U2S3, Q5VVW2, Q5XHY7, Q61502, Q6NZC7, Q6P158, Q6P5D3, Q6PDI6, Q6PGC1, Q75E61, Q76LS9, Q7M760, Q7TSI3, Q7XI08, Q7Z478, Q8C437, Q8GY87, Q8H106, Q8N5J2, Q8NBR6

Diamond homologs: A3KQS4, P53155, Q2KI23, Q2KJ22, Q5BJQ2, Q5R7G8, Q6PDI6, Q76LS9, Q8N5J2, Q8NBR6, Q08930, Q09874

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	73
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1785 predictions. Top by Δscore:

Variant	Effect	Δscore
1:150999363:CATTA:C	donor_loss	1.0000
1:150999365:TTA:T	donor_loss	1.0000
1:150999366:TACC:T	donor_loss	1.0000
1:150999367:A:C	donor_loss	1.0000
1:150999368:C:G	donor_loss	1.0000
1:150999427:T:A	donor_gain	1.0000
1:150999516:C:CT	acceptor_gain	1.0000
1:150999516:C:T	acceptor_gain	1.0000
1:151000532:A:AC	donor_gain	1.0000
1:151000532:AAAAT:A	donor_gain	1.0000
1:151000533:A:C	donor_gain	1.0000
1:151000612:CATT:C	acceptor_gain	1.0000
1:151000614:TT:T	acceptor_gain	1.0000
1:151000616:C:CC	acceptor_gain	1.0000
1:150997753:C:CC	acceptor_gain	0.9900
1:150998159:G:C	donor_gain	0.9900
1:150998172:G:C	donor_gain	0.9900
1:150999433:G:C	donor_gain	0.9900
1:150999507:CAGGC:C	acceptor_gain	0.9900
1:150999512:C:CC	acceptor_gain	0.9900
1:150999512:CT:C	acceptor_loss	0.9900
1:150999513:T:G	acceptor_loss	0.9900
1:150999517:A:T	acceptor_gain	0.9900
1:150999981:A:AC	acceptor_gain	0.9900
1:150999981:A:C	acceptor_gain	0.9900
1:150999992:C:CT	acceptor_gain	0.9900
1:150999993:A:T	acceptor_gain	0.9900
1:151000451:CCTCA:C	donor_loss	0.9900
1:151000452:CTCA:C	donor_loss	0.9900
1:151000453:TCACC:T	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000195456 (1:150998226 C>A,G,T), RS1000283227 (1:151005157 G>C), RS1000397284 (1:151001521 T>C), RS1000499435 (1:150996792 C>T), RS1001007281 (1:151003622 C>A,T), RS1001015652 (1:151003230 C>A,G,T), RS1001561979 (1:150998970 G>C), RS1001671565 (1:150999976 G>A), RS1001685033 (1:151006299 A>G), RS1001707567 (1:150998458 C>T), RS1001714790 (1:151005912 A>C), RS1002308147 (1:151001869 G>A), RS1002634003 (1:151007926 G>A), RS1003116946 (1:151000258 A>G), RS1003273316 (1:151002001 C>A,G,T)

Disease associations

OMIM: gene MIM:618407 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST000649_7	Chronic kidney disease	1.000000e-12
GCST001966_1	Rhegmatogenous retinal detachment	1.000000e-07
GCST005951_38	Body mass index	4.000000e-09
GCST007515_18	Type 2 diabetes	8.000000e-08
GCST007516_21	Type 2 diabetes (adjusted for BMI)	7.000000e-07
GCST007517_2	Type 2 diabetes	6.000000e-08
GCST007518_4	Type 2 diabetes (adjusted for BMI)	6.000000e-08
GCST009379_32	Type 2 diabetes	4.000000e-06
GCST009379_33	Type 2 diabetes	3.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
afuresertib	increases expression	1
FR900359	decreases phosphorylation	1
bisphenol F	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	increases activity, affects binding, decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
tris(2-butoxyethyl) phosphate	affects expression	1
sulforaphane	decreases expression	1
sodium arsenite	decreases expression	1
gossypol acetic acid	decreases expression	1
cupric chloride	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	decreases expression	1
bisphenol S	increases expression	1
jinfukang	affects cotreatment, increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	increases expression	1
Leflunomide	decreases expression	1
Acetaminophen	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Cadmium	decreases expression	1
Caffeine	increases phosphorylation	1
Cisplatin	increases expression, affects cotreatment	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Formaldehyde	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9KB	Ubigene HEK293 MINDY1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.